FDA strikes twice for Cerus

Three days after FDA approved the Intercept Blood System for plasma, Cerus Corp. (NASDAQ:CERS) announced the agency approved the company's Intercept system for platelets. Cerus shares rose $0.25 to $6.41 on Friday; they have gained 34% since Tuesday's close, before the plasma system approval was announced.

Cerus already markets the system for plasma and for platelets in Europe, the Commonwealth of Independent States and the Middle East. ...